- Home
- CRF vs AVDL Comparison
CRF vs AVDL Comparison
Compare CRF & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRF
- AVDL
- Stock Information
- Founded
- CRF 1973
- AVDL 2015
- Country
- CRF United States
- AVDL Ireland
- Employees
- CRF N/A
- AVDL N/A
- Industry
- CRF Finance/Investors Services
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- CRF Finance
- AVDL Health Care
- Exchange
- CRF Nasdaq
- AVDL Nasdaq
- Market Cap
- CRF 926.5M
- AVDL 764.3M
- IPO Year
- CRF N/A
- AVDL 1996
- Fundamental
- Price
- CRF $7.54
- AVDL $8.31
- Analyst Decision
- CRF
- AVDL Strong Buy
- Analyst Count
- CRF 0
- AVDL 7
- Target Price
- CRF N/A
- AVDL $18.86
- AVG Volume (30 Days)
- CRF 1.5M
- AVDL 1.4M
- Earning Date
- CRF 01-01-0001
- AVDL 03-03-2025
- Dividend Yield
- CRF 17.55%
- AVDL N/A
- EPS Growth
- CRF N/A
- AVDL N/A
- EPS
- CRF 1.40
- AVDL N/A
- Revenue
- CRF $11,461,786.00
- AVDL $169,117,000.00
- Revenue This Year
- CRF N/A
- AVDL $50.78
- Revenue Next Year
- CRF N/A
- AVDL $32.44
- P/E Ratio
- CRF $5.50
- AVDL N/A
- Revenue Growth
- CRF 6.53
- AVDL 504.79
- 52 Week Low
- CRF $6.52
- AVDL $7.39
- 52 Week High
- CRF $9.75
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- CRF 31.71
- AVDL 46.11
- Support Level
- CRF $7.50
- AVDL $7.46
- Resistance Level
- CRF $7.75
- AVDL $7.97
- Average True Range (ATR)
- CRF 0.27
- AVDL 0.41
- MACD
- CRF -0.02
- AVDL 0.02
- Stochastic Oscillator
- CRF 10.84
- AVDL 37.50
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.